|
gptkbp:instanceOf
|
gptkb:drug
NMDA receptor antagonist
dissociative anesthetic
|
|
gptkbp:abusePotential
|
moderate
|
|
gptkbp:approvedBy
|
1970 (US)
|
|
gptkbp:ATCCode
|
gptkb:N01AX03
|
|
gptkbp:brand
|
gptkb:Ketalar
gptkb:Ketanest
gptkb:Ketaset
gptkb:Ketavet
|
|
gptkbp:CASNumber
|
6740-88-1
|
|
gptkbp:chemicalFormula
|
C13H16ClNO
|
|
gptkbp:contraindication
|
history of psychosis
severe hypertension
|
|
gptkbp:discoveredBy
|
gptkb:Calvin_Stevens
|
|
gptkbp:discoveredIn
|
1962
|
|
gptkbp:eliminationHalfLife
|
2.5-3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasEnantiomer
|
gptkb:arketamine
gptkb:esketamine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ketamine
|
|
gptkbp:IUPACName
|
(RS)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
|
|
gptkbp:legalStatus
|
gptkb:Schedule_III_(US)
Prescription only (various countries)
|
|
gptkbp:mainStreet
|
gptkb:Kit_Kat
gptkb:Vitamin_K
gptkb:Special_K
K
|
|
gptkbp:mechanismOfAction
|
NMDA receptor antagonism
interaction with monoaminergic receptors
interaction with opioid receptors
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
237.725 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL402
3821
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
intranasal
|
|
gptkbp:sideEffect
|
confusion
nausea
dissociation
hallucinations
elevated blood pressure
|
|
gptkbp:UNII
|
690G0D6V8H
|
|
gptkbp:usedFor
|
pain management
treatment-resistant depression
anesthesia
status epilepticus
sedation
|
|
gptkbp:usedIn
|
gptkb:veterinary_medicine
|
|
gptkbp:bfsParent
|
gptkb:memantine
|
|
gptkbp:bfsLayer
|
5
|